Hanxiong Liu

Hanxiong Liu

Auto-generated profile, based on publicly available information

Hanxiong Liu

Department of Cardiology, The Third People’s Hospital of Chengdu

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
WHWenchao Huang
Wenchao Huang
HSHuaxin Sun
Huaxin Sun
YTYan Tang
Yan Tang
YLYan Luo
Yan Luo
HLHanxiong Liu
Hanxiong Liu
Purpose: To investigate the effect and comprehensive predictive value of the platelet-to-lymphocyte ratio (PLR) for long-term recurrence in patients with atrial fibrillation (AF) post ablation. Patients and Methods: We retrospectively analysed 638 consecutive AF patients who underwent ablation, including 302 (47.3%) with paroxysmal AF and 336 (52.7%) with nonparoxysmal AF. Patients were grouped into the recurrence and nonrecurrence groups. Results: After a mean follow-up of 15.1± 9.3 months, 175 patients (27.4%) with AF had long-term recurrence, including 114 patients (33.9%) with nonparoxysmal AF and 61 patients (20.2%) with paroxysmal AF. In the entire cohort and in patients with nonparoxysmal AF, but not in those with paroxysmal AF, the PLR was significantly higher in the recurrence group than in the nonrecurrence group (P< 0.05). After adjusting for the APPLE score, the PLR as a continuous variable independently predicted AF recurrence (hazard ratio [HR], 1.003; 95% confidence interval [CI], 1.001– 1.005; P< 0.01). The addition of the PLR to the APPLE score improved its predictive ability for recurrence (the C-statistic value increased from 0.645 to 0.675, P=0.02; the net reclassification improvement was 0.221, 95% CI 0.049– 0.394, P=0.01; and the integrated discrimination improvement was 0.029, 95% CI 0.013– 0.045, P< 0.01). For nonparoxysmal AF, the PLR was stratified into tertiles, the PLR independently increased the nonparoxysmal AF recurrence risk after adjusting for multiple confounding factors (HR, 1.393; 95% CI, 1.102– 1.762; P< 0.01), and the addition of the PLR to the left atrial diameter improved its predictive ability for arrhythmia recurrence (the C-statistic value increased from 0.601 to 0.667, P< 0.01). Conclusion: The PLR is an independent predictive factor of long-term AF recurrence post ablation after adjusting for the APPLE score and can improve the predictive ability and clinical usefulness of the APPLE score. However, the PLR is an effective predictor of recurrence in patients with nonparoxysmal AF rather than in paroxysmal AF. Plain Language Summary: AF is a common cardiac arrhythmia that can be treated by catheter ablation. Even though the application of ablation has increased in clinical practice, the AF recurrence rate remains stubbornly high. Predicting the risk of recurrence would allow the optimization of AF treatment and management strategies. The impact of inflammation on atrial fibrillation recurrence is unperceived in the existing AF risk scores. Therefore, we investigated the predictive ability of the platelet-to-lymphocyte ratio, a marker of systemic inflammation that can be easily calculated following routine blood analysis, in estimating the risk of AF recurrence. We found that in the entire cohort and in patients with nonparoxysmal AF, but not in those with paroxysmal AF, the PLR ratio was significantly higher in the recurrence group than in the nonrecurrence group. Adding the platelet-to-lymphocyte ratio to the APPLE risk score improved its ability to predict AF in the entire cohort. In patients with nonparoxysmal AF, the addition of the RLR to the left atrial diameter improved its predictive accuracy. However, the PLR ratio did not predict recurrence of paroxysmal AF. Interestingly, we found that recurrence risk scores, such as the APPLE score and CHA2DS2-VASc, had no predictive value for nonparoxysmal AF. Therefore, the addition of the PLR to the APPLE score should be considered in evaluating AF recurrence risk for patients with an unknown type, and the addition of the PLR to the left atrial diameter should be performed to predict AF recurrence in patients with nonparoxysmal AF.

2 July 2024 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
WHWenchao Huang
Wenchao Huang
HSHuaxin Sun
Huaxin Sun
SXShiqiang Xiong
Shiqiang Xiong
YLYan Luo
Yan Luo
YTYan Tang
Yan Tang
HLHanxiong Liu
Hanxiong Liu
Background: There is sufficient evidence that women with atrial fibrillation (AF) have a greater symptom burden than men with AF and are more likely to experience recurrence after catheter ablation. However, the mechanisms underlying these sex differences are unclear. Methods: We prospectively enrolled 125 consecutive patients, including 40 non-AF patients and 85 AF patients, who underwent high-density voltage mapping during sinus rhythm and AF patients who underwent first ablation. Results: Overall, 37 (44%) female patients with AF and 24 (60%) female non-AF patients with a mean age of 61.7 ± 11.6 years and 53.6 ± 16.7 years, respectively, were enrolled in this study. The results showed that the atrial voltage of female AF patients was significantly lower than that of male AF patients (1.11 ± 0.58 mV vs. 1.53 ± 0.65 mV; P = 0.003), while there were no significant sex differences in non-AF patients (3.02 ± 0.86 mV vs. 3.21 ± 0.84 mV; P = 0.498). Multiple linear regression analysis revealed that female sex (− 0.29, 95% confidence interval [CI] − 0.64 to − 0.13, P = 0.004) and AF type (− 0.32, 95% CI − 0.69 to − 0.13, P = 0.004) were the only factors independently associated with voltage. Compared with men, women in the paroxysmal AF group had a 3.5-fold greater incidence of recurrence (adjusted hazard ratio 4.49; 95% CI 1.101–18.332, P = 0.036). Both globally and regionally, the results showed that sex-related differences in voltage values occurred prominently in paroxysmal AF patients but not in nonparoxysmal AF patients. Conclusion: Sex-related differences in atrial substrates and arrhythmia-free survival were found in paroxysmal AF patients, suggesting the existence of sex-related pathophysiological factors.

13 August 2024 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
WHWenchao Huang
Wenchao Huang
HSHuaxin Sun
Huaxin Sun
YLYan Luo
Yan Luo
SXShiqiang Xiong
Shiqiang Xiong
YTYan Tang
Yan Tang
HLHanxiong Liu
Hanxiong Liu
The benefits of rhythm control in the early atrial fibrillation (AF) are increasingly recognized. This study aimed to investigate whether early AF ablation contributes to long-term sinus rhythm maintenance and to identify a suitable predictive score. According to the diagnosis-to-ablation time, this study prospectively enrolled 245 very early AF patients, 262 early AF patients, and 588 late AF patients for radiofrequency ablation from June 2017 to December 2022. Clinical data, risk scores and follow-up results were collected and analyzed. Baseline characteristics were similar among the three cohorts. During a median follow-up period of 26 months, AF recurrence was observed in 61 (24.9%), 66 (25.2%), and 216 (36.7%) patients in the very early, early, and late AF cohorts, respectively. In the multivariable-adjusted model, very early and early AF were associated with a reduced risk of AF recurrence, with hazard ratios of 0.72 (95% confidence interval [CI]: 0.52-0.99) and 0.57 (95% CI: 0.41-0.78), respectively. The APPLE score demonstrated the highest predictive power for very early AF, with an area under the curve (AUC) of 0.74. However, its predictive power decreased with time from diagnosis, and a low predictive power for late AF (AUC=0.58). In addition, the time-dependent concordance index showed consistent results. For very early AF, the Akaike information criterion and decision curve analysis showed that APPLE had the highest predictive value. Very early AF ablation was associated with a lower recurrence rate, and the APPLE score can provide a higher predictive value for them. (URL: https://www.chictr.org.cn/; Unique identifier: ChiCTR-OIN-17013021).

20 January 2025 in International Immunopharmacology
Verified
Journal Article
Open access
JSJun Shen
Jun Shen
JLJunqing Liang
Junqing Liang
PYPing Yuan
Ping Yuan
HSHuaxin Sun
Huaxin Sun
MRManzeremu Rejiepu
Manzeremu Rejiepu
BTBaopeng Tang
Baopeng Tang
The antiarrhythmic effect of melatonin(MLT) has been demonstrated in several studies; however, this hypothesis has recently been contested. Our research seeks to determine if exogenous MLT supplementation can reduce atrial fibrillation (AF) susceptibility due to sleep deprivation (SD) by addressing Ca2+ mishandling and atrial mitochondrial oxidative stress. Adult rats received daily MLT or vehicle injections and were exposed to a modified water tank. We evaluated MLT's impact on AF susceptibility by analyzing atrial electrical and structural changes, calcium handling, and oxidative stress markers. Techniques used included electrophysiological recording, echocardiography, optical mapping, histopathology, and molecular assays to understand MLT's protective effects against sleep deprivation-induced AF. Our findings indicate that MLT treatment effectively mitigates SD-induced AF, safeguards against atrial structural alterations, diminishes mitochondrial oxidative stress and normalizes calcium dynamics. Notably, MLT corrected calcium transient duration (CaD), action potential duration (APD), and conduction heterogeneity, shortened calcium transient refractoriness, and improved arrhythmogenic atrial alternans and spatially discordant alternans, thereby lowering the arrhythmogenic potential of the atria during sleep deprivation. In terms of mechanisms, MLT prevents SD-induced activation of ROS/CaMKII in atrial cardiomyocytes, reversing calcium transient refractoriness and inhibiting arrhythmogenic alternans. MLT significantly decreases the susceptibility to SD-induced AF by ameliorating mitochondrial oxidative stress and Ca2+ mishandling. These findings suggest a potential therapeutic application of MLT as an antiarrhythmic intervention for SD-related AF and underscore the need for further investigation, including clinical studies, to validate these mechanisms.

20 December 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
WHWenchao Huang
Wenchao Huang
HSHuaxin Sun
Huaxin Sun
YLYan Luo
Yan Luo
YTYan Tang
Yan Tang
SXShiqiang Xiong
Shiqiang Xiong
HLHanxiong Liu
Hanxiong Liu
We probed whether the addition of hemoglobin (HGB) or the female sex (SEX) as variables would provide additional prognostic value to the APPLE score. An optimized APPLE score was used to evaluate the AF recurrence risk in the consecutive populations with AF post-catheter ablation including the development (n=562) and validation (n=239) cohorts. In the populations of AF recurrence, most patients were female sex (103/164, 62.8%), and had the lower HGB levels. After adjusting for the APPLE score, HGB level (Odds Ratio [OR], 0.828; 95% Confidence Interval [CI], 0.749-0.915; P<0.001) and female sex (OR, 1.596; 95% CI, 1.140-2.235; P=0.006) independently predicted AF recurrence. Adjusting the APPLE score by HGB variable improved its predictive ability for AF recurrence (C-statistic value from 0.675 to 0.711, P=0.010), which also increased the C-indexes in the external validation (from 0.653 to 0.725, p=0.023). Female sex variable also enhanced the C-statistic value of the APPLE score for AF recurrence at the both development and external validation (C-indices from 0.675 to 0.691, P=0.004; C-indices from 0.653 to 0.704, p=0.037, respectively). Decision curve analysis showed that the HGB plus APPLE score was better than the SEX plus APPLE score in predicting AF recurrence in two following AF populations. Inclusion of HGB level and female sex variables improved the predictability and clinical usefulness of adjusted APPLE score. Adjustment of the APPLE score by HGB levels may provide better predictive value than inclusion of the female sex variable.

6 January 2025 in Regenerative Biomaterials
Verified
Journal Article
Open access
PYPengcheng Yu
Pengcheng Yu
WLWeiqi Lu
Weiqi Lu
HSHuaxin Sun
Huaxin Sun
CHChengchen Huang
Chengchen Huang
XZXiaolin Zhou
Xiaolin Zhou
XSXia Sheng
Xia Sheng
Postoperative atrial fibrillation (POAF) is the most prevalent form of secondary atrial fibrillation and increases the risk of adverse cardiovascular outcomes, such as stroke, heart failure and increased mortality. Herein, we designed an andrographolide (Andr)-loaded degradable polymer patch to deliver the drug directly to the atrial tissue for prevention of POAF. The sterile pericarditis (SP) rat model was adopted for highly relationship to clinical practice. The patch-released Andr effectively reduced the incidence of atrial fibrillation from 90 to 20%, and alleviated local atrial inflammation and oxidative stress in vivo, by using electrophysiological detection and histological analysis such as immunofluorescence, western blot and PCR. In HL-1 cells, we found the use of Andr-loaded patch could strongly inhibit the cell death, reactive oxygen species (ROS) generation and mitochondrial injury caused by LPS. Meanwhile, the use of Andr-loaded patch could effectively inhibited macrophages polarize towards M1. Mechanistically, we verified that the regulation of the cytoplasm and mitochondria Ca2+ and ROS dynamic balance was quite important both in vivo and in vitro. Our strategy proved by regulating the inflammatory microenvironment, ROS balance and Ca2+ homeostasis and the Andr-loaded atrial patch was effective for POAF in the SP rat model. The electrical signal of atrial stromal reentry in the case of this model was successfully mined, and the results of calcium channel were basically consistent with that of electrical signal channel. In addition, we have reported the infiltration and polarization of local inflammatory cells in the atrial of POAF at the tissue section level. Our study served as a new inspiration for the treatment of arrhythmic diseases and other ROS- and Ca2+- associated local illnesses.